Corxel Pharmaceuticals raised up to $287 million in a Series D financing to advance its oral GLP‑1 receptor agonist through phase 2/3 obesity studies. The China‑founded company has shifted headquarters to New Jersey and is positioning the oral program for global development. Investors provided growth capital to accelerate clinical development amid continued market interest in obesity therapies. Corxel’s fundraising underscores ongoing capital flow into GLP‑1 and oral incretin modalities as sponsors attempt to capture share across weight‑loss and metabolic indications.